🧬Unveiling Our New Logo: A Symbol of Hope and Innovation🧬 Introducing our brand new logo symbolizes our unwavering commitment to progress and excellence in the healthcare industry. This refreshed identity embodies our core values and aspirations for the future. Our new logo boats simplified hexagons, representing the molecular structure of DNA bases. The merging of two hexagons symbolizes the DNA double helix and the concept of "infinite hope." The vibrant blue hue conveys professionalism, innovation, and a deep sense of care. #ACTGenomics #genomics #personalizedmedicine #precisionmedicine #futureofhealthcare
關於我們
ACT Genomics is a world-leading genomic test solution provider. Our mission is to make personalized medicine accessible to all. We offer precision medicine services globally. Combining tumor biology, cancer genomics, and bioinformatics experts to provide treatment guidelines for solid tumors, relapse, and drug resistance, as well as cancer monitoring, risk assessment, and immunotherapy evaluation. We are dedicated to turning every cancer patient's genetic information into actionable resolutions through cutting-edge next-generation sequencing (NGS) platforms, bioinformatics analysis, and comprehensive service offerings. Our NGS platform, coupled with sophisticated bioinformatics tools and curated proprietary databases, enables us to deliver reliable results for clinical and research purposes, and our data visualization technologies make the scientific results easily understandable for everyone. Our clinical services include cancer prevention, early detection, treatment selection, and disease monitoring. Our genomic assays offer comprehensive cancer genomic profiling and treatment options for patients with cancer and provide insights into biomarker discovery and patient stratification for clinical trials.
- 網站
-
https://www.actgenomics.com
外部ACT Genomics連結
- 產業
- 生物技術研究
- 公司規模
- 201-500 名員工
- 總部
- Taipei
- 類型
- 私人所有
- 創立時間
- 2014
- 專長
- cancer biology、molecular information、next generation sequencing、bioinformatics、precision medicine、cancer drug development、oncology和cancer genomics sequencing
地點
-
主要
查詢路線
3F ., No.345, Xinhu 2nd Rd., Neihu Dist
Taipei City, Taiwan
11494 TWTaipei
-
查詢路線
10 Anson Road, #05-01 International Plaza
089058 SGSingaporeSingapore
-
查詢路線
No.15 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok. NT
Units 803 – 807, 8F, Building 15W
Units 803 – 807 HKPak Shek Kok. NTHong Kong
-
查詢路線
No.4, 4/5 Unit 1503, Unit 1509, Central Tower, 15/F, Ratchadamri Road, Pathumwan
TH Bangkok
ACT Genomics員工
動態消息
-
ACT Genomics is with #ESMOASIA 2024 in #Singapore this weekend. We are excited to discuss #PrecisionMedicine and #NGS practices with all attendees onsite. Please don't hesitate to visit us at booth #D401. 行動基因本周末於新加坡的 #ESMOASIA 2024 展出，敬邀各位與會者至攤位 #D401 與我們一同討論 #精準醫療 與 #次世代基因定序！
-
-
ACT Genomics will be showcasing out best solutions in the 2024 #HealthcareEXPO. Please join us onsite for a deepdive into #NGS and #PrecisionMedicine discussion. We look forward to seeing you there! 行動基因將會在2024 #醫療科技展 展出我們的檢測服務，請加入我們的行列一同討論 #次世代基因定序 以及 #精準醫療，期待在現場見到各位！
-
-
We are honored to join #TaiwanEXPO this year in Bangkok, #Thailand 🇹🇭. A great opportunity to introduce the innovative cancer genomic solutions from Taiwan overseas.
-
ACT Genomics is proud to share the collaboration with Friends of Cancer Research on HRD harmonization project. We are honored to partner with the organization for the second time after the TMB harmonization project.
New Friends of Cancer Research findings in American Society of Clinical Oncology (ASCO) #jcooa examine variability in outputs from homologous recombination deficiency (HRD) assays assessing a common sample set. HRD is a biomarker used to determine eligibility for Poly ADP-ribose Polymerase Inhibitors (PARPi) to treat high-grade serous ovarian carcinoma (HGSOC). The findings demonstrate variability in HRD results across assays, suggesting the need for consistent and aligned strategies in biomarker selection for clinical trials and clinical decision-making in oncology drug development. Read the full publication here: bit.ly/3YSeTck This manuscript is the final output from Friends HRD Project, which aims to answer the question: Does Homologous Recombination Deficiency (HRD) status differ across HRD assays and what contributes to variability? Learn more about Friends HRD Project here: https://lnkd.in/dta-3D5y #HRDFriends Thank you to our coauthors: Hillary Andrews, PhD, Lisa McShane, Elis C. Kohn, Rebecca Arend, Chris Karlovich, Kaitlyn Kincaid, Douglas Laird, Ming-Chung Li, Ethan Sokol, Elizabeth R. Starks, Shulin Bi, Lauren Brunner, Alyssa Chapman, Li Chen, Tommaso Coletta, Yuan Ding, Bailee Dover, McKenzie Foxall, Mohit Gupta, Zan Halford, Andrea G. Kahn, Nikita Kotlov, Yi-Hsuan Lucy Lai, Alexander J. Lazar, Wenjie Li, Brittany Avin McKelvey, Hyunjun Nam, Sarabjot Pabla, Pegah Safabakhsh, Daniel Saul, Albrecht Stenzinger, Timothy J. Taxter, M.D., Zhiwei Zhang, Yingdong Zhao, ShiPing Zou, Mark Stewart, Jeff Allen. This work is possible through a large-scale partnership. Thank you to the following partners: Friends of Cancer Research, National Cancer Institute (NCI), University of Alabama at Birmingham, Frederick National Laboratory for Cancer Research, Pfizer, Foundation Medicine, Invitae, Amoy Diagnostics, PathAI, SOPHiA GENETICS, Illumina, Thermo Fisher Scientific, Diagnostic Laboratory Services, BostonGene, ACT Genomics, The University of Texas MD Anderson Cancer Center, Burning Rock Dx, NeoGenomics Laboratories, Labcorp Oncology (OmniSeq), Guardant Health, Bionano Genomics, Inc., University Hospital Heidelberg (UKHD), Tempus AI, Pillar Biosciences Incorporated.
-
Can You Prevent #HereditaryCancer? Understand the risk-reduction strategies! Hereditary cancers may not be possible to prevent entirely, but understanding your genetic risks can empower you to take proactive steps to reduce the chances of cancer developing or catching it early when it’s most treatable. Join us in understanding more about the strategies: https://smpl.is/9smxl
-
-
We’re excited to announce a new partnership between ACT Genomics and mProbe Inc. to advance precision medicine in Asia! This collaboration will focus on expanding access to mProbe's innovative proteomics technology for oncology diagnostics across key markets. Together, we aim to enhance cancer diagnosis and treatment outcomes. #PrecisionMedicine #Oncology #AsianMarkets #HealthcareInnovation The full article: https://smpl.is/9rpad
-
-
Let's take a deep dive into hereditary cancer syndromes. They are genetic disorders that significantly increase an individual's risk of developing certain types of cancer. Unlike sporadic cancers, which occur due to random genetic mutations over a person's lifetime, hereditary cancers result from inherited gene mutations passed down through parents. Full article: https://smpl.is/9rh5z